Non‐fatal PE (3 to 12 months) · participants with diagnosed DVT
Oral factor Xa inhibitors showed no clear difference in non‐fatal PE (3 to 12 months) compared with conventional anticoagulation (moderate certainty).
1 finding from 1 review
All‐cause mortality (3 to 6 months) · participants with diagnosed DVT
Oral factor Xa inhibitors showed no clear difference in all‐cause mortality (3 to 6 months) compared with conventional anticoagulation (moderate certainty).
1 finding from 1 review
Major bleeding · participants with diagnosed DVT
Oral factor Xa inhibitors leads to lower major bleeding (3 to 12 months) compared with conventional anticoagulation (high certainty).
1 finding from 1 review
Recurrent DVT (3 to 12 months) · participants with diagnosed DVT
Oral DTIs showed no clear difference in recurrent DVT (7 months) compared with conventional anticoagulation (moderate certainty).
1 finding from 1 review
Fatal PE (3 to 12 months) · participants with diagnosed DVT
Oral DTIs showed no clear difference in fatal PE (7 months) compared with conventional anticoagulation (moderate certainty).
1 finding from 1 review
Non‐fatal PE (3 to 12 months) · participants with diagnosed DVT
Oral DTIs showed no clear difference in non‐fatal PE (7 months) compared with conventional anticoagulation (moderate certainty).
1 finding from 1 review
All‐cause mortality (7 months) · participants with diagnosed DVT
Oral DTIs showed no clear difference in all‐cause mortality (7 months) compared with conventional anticoagulation (moderate certainty).
1 finding from 1 review
Major bleeding · participants with diagnosed DVT
Oral DTIs leads to lower major bleeding (7 months) compared with conventional anticoagulation (high certainty).
1 finding from 1 review
Recurrent VTE · participants with diagnosed DVT
Oral factor Xa inhibitors showed no clear difference in recurrent VTE (3 to 12 months) compared with conventional anticoagulation (moderate certainty).
1 finding from 1 review
Recurrent DVT (3 to 12 months) · participants with diagnosed DVT
Oral factor Xa inhibitors showed no clear difference in recurrent DVT (3 to 12 months) compared with conventional anticoagulation (moderate certainty).
1 finding from 1 review
Fatal PE (3 to 12 months) · participants with diagnosed DVT
Oral factor Xa inhibitors showed no clear difference in fatal PE (3 to 12 months) compared with conventional anticoagulation (moderate certainty).
1 finding from 1 review
Recurrent PE · patients with a pulmonary embolism, confirmed by standard imaging techniques
Oral direct thrombin inhibitors (DTIs) showed no clear difference in recurrent PEa compared with conventional anticoagulation (moderate certainty).
1 finding from 1 review
All‐cause mortality · patients with a pulmonary embolism, confirmed by standard imaging techniques
Oral factor Xa inhibitors showed no clear difference in all‐cause mortality compared with conventional anticoagulation (moderate certainty).
1 finding from 1 review
Major bleedinge · patients with a pulmonary embolism, confirmed by standard imaging techniques
Oral factor Xa inhibitors showed no clear difference in major bleedinge compared with conventional anticoagulation (low certainty).
1 finding from 1 review
Health‐related quality of life · patients with a pulmonary embolism, confirmed by standard imaging techniques
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrent VTEc · patients with a pulmonary embolism, confirmed by standard imaging techniques
Oral direct thrombin inhibitors (DTIs) showed no clear difference in recurrent VTEc compared with conventional anticoagulation (moderate certainty).
1 finding from 1 review
DVTd · patients with a pulmonary embolism, confirmed by standard imaging techniques
Oral direct thrombin inhibitors (DTIs) showed no clear difference in DVTd compared with conventional anticoagulation (moderate certainty).
1 finding from 1 review
All‐cause mortality · patients with a pulmonary embolism, confirmed by standard imaging techniques
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Major bleedinge · patients with a pulmonary embolism, confirmed by standard imaging techniques
Oral direct thrombin inhibitors (DTIs) showed no clear difference in major bleedinge compared with conventional anticoagulation (moderate certainty).
1 finding from 1 review
Health‐related quality of life · patients with a pulmonary embolism, confirmed by standard imaging techniques
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found